Wells Fargo & Company Abb Vie Inc. Put Options Transaction History

Wells Fargo & Company

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 13, 2024	BUY	$154.79 - $180.76 $526,286 - $614,584	3,400 Added 20.48%	20,000 $3.43 Million
Q1 2024 May 10, 2024	SELL	$159.82 - $182.1 $12.2 Million - $13.9 Million	-76,500 Reduced 82.17%	16,600 $3.02 Million
Q3 2023 Nov 13, 2023	BUY	$133.59 - $154.65 $280,539 - $324,765	2,100 Added 2.31%	93,100 $13.9 Million
Q2 2023 Aug 15, 2023	SELL	$132.51 - $164.9 $5.21 Million - $6.48 Million	-39,300 Reduced 30.16%	91,000 $12.3 Million
Q1 2023 May 12, 2023	BUY	$144.61 - $166.54 $3.96 Million - $4.56 Million	27,400 Added 26.63%	130,300 $20.8 Million
Q4 2022 Feb 13, 2023	BUY	$138.31 - $165.87 $14.2 Million - $17 Million	102,500 Added 25625.0%	102,900 $16.6 Million
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $19.7 Million - $24.5 Million	-149,600 Reduced 99.73%	400 $65,000
Q4 2020 Feb 09, 2021	BUY	$80.49 - $108.67 $11.8 Million - $16 Million	146,900 Added 4738.71%	150,000 $53,000
Q2 2020 Aug 13, 2020	SELL	$73.37 - $98.18 $95,381 - $127,634	-1,300 Reduced 29.55%	3,100 $15,000
Q1 2020 May 14, 2020	BUY	$64.5 - $97.79 $283,800 - $430,276	4,400 New	4,400 $12,000

3,695

1.27B

13M

9.79M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $348B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.